Savara (DE:YB4P)
NASDAQ:YB4P
YB4P Stock Chart & Stats
€4.89
€0.02(0.68%)
At close: 4:00 PM EST
€4.89
€0.02(0.68%)
Day’s Range― - ―
52-Week Range€1.71 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€902.85M
Enterprise Value€1.06B
Total Cash (Recent Filing)€202.77M
Total Debt (Recent Filing)€30.07M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 06, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.68Price Target Upside97.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€2.74M
Bulls Say, Bears Say
Bulls Say
Niche Rare-disease FocusSavara’s concentrated strategy on rare pulmonary diseases and an inhaled lead program for PAP creates durable commercial optionality: smaller competitive sets, clearer regulatory pathways, and the potential for premium pricing and durable demand if clinical success translates to approval.
Manageable LeverageRelative to typical biotech financing risk, low reported debt gives the company financial flexibility for near-term R&D spend. Manageable leverage reduces immediate solvency pressure and preserves the ability to raise non-dilutive capital or execute strategic partnerships.
Internal Leadership ContinuityPromoting an internal COO with finance, capital-raising and BD experience to CFO/COO preserves institutional knowledge, supports coordinated operational and financing execution, and may reduce transition risk versus an external hire during critical development milestones.
Bears Say
No Revenue And Widening LossesThe absence of revenue and materially increasing net losses indicate the company remains pre-commercial and dependent on external funding. Persistent deficits erode shareholder equity and lengthen the timeline to self-sustaining operations unless clinical programs succeed and generate revenue.
High And Accelerating Cash BurnRapidly growing cash outflows show R&D and operating expenses translating into real cash consumption. Sustained negative free cash flow raises near-term financing needs and dilution risk, constraining strategic optionality and increasing sensitivity to capital markets conditions.
Expanded Share Authorization (dilution Risk)Doubling authorized shares and enlarging the equity award pool provides financing flexibility but structurally raises dilution risk over time. For a pre-revenue biotech, expanded share capacity makes future equity raises more likely and can erode existing ownership and per-share economic value.
Savara News
YB4P FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was €1.71 and its highest was €5.90 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is €902.85M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on May 12, 2026. The company reported -€0.129 earnings per share for the quarter, missing the consensus estimate of -€0.116 by -€0.013.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.12.
How many shares outstanding does Savara have?
Savara has 204,927,220 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -€0.129 in its last earnings report, missing expectations of -€0.116. Following the earnings report the stock price went down -0.492%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in DE:YB4P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.68 (97.89% Upside)
€9.68 (97.89% Upside)
Blogger Sentiment
Bullish
DE:YB4P Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.14%
12-Months-Change
Fundamentals
Return on Equity
-87.19%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
YB4P Stock 12 Month Forecast
Average Price Target
€9.68
▲(97.89% Upside)
Technical Analysis
Options Prices
Currently, No data available
---